Larkin Cristina 4
4 · Spero Therapeutics, Inc. · Filed Dec 18, 2020
Insider Transaction Report
Form 4
Larkin Cristina
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2020-12-16$5.90/sh+12,000$70,800→ 13,500 total - Sale
Common Stock
2020-12-16$19.00/sh−12,000$228,000→ 1,500 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-16−12,000→ 8,434 totalExercise: $5.90Exp: 2027-07-05→ Common Stock (12,000 underlying)
Footnotes (2)
- [F1]All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 12,000 shares).
- [F2]All shares underlying this option were fully vested as of March 7, 2020.